<DOC>
	<DOCNO>NCT00118781</DOCNO>
	<brief_summary>This multinational , double-blind , placebo-controlled trial design ass whether iseganan , apply topically oral cavity , prevent ventilator-associated pneumonia among patient intubate mechanically ventilated survive 14 day .</brief_summary>
	<brief_title>Trial Iseganan Prevention Ventilator-Associated Pneumonia</brief_title>
	<detailed_description>Patients randomize receive first dose Study Drug within 24 hour oral/nasal intubation initiation mechanical ventilation . The Study Period begin first administration Study Drug ( Study Day 1 ) . Three mL Study Drug ( 9 mg iseganan match placebo ) apply visible surface oral cavity oral portion endotracheal tube ( non-tracheostomy patient ) every 4 hour Study Day 14 , diagnosis microbiologically-confirmed pneumonia ( base central laboratory result ) extubation , whichever occur first . All patient evaluate clinically define pneumonia least daily , diagnosed , blood specimen collect cultured , bronchoscopic alveolar lavage ( BAL ) specimen ( intubated patient ) respiratory secretion specimen ( extubated patient ) obtain PRIOR initiate change systemic antimicrobial therapy .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<criteria>Greater equal 18 year age Orally/nasally intubate receive mechanical ventilation &lt; 24 hour prior schedule randomization administration first dose Study Drug , judgment attend physician , expect remain intubated mechanically ventilate least 48 hour Expected survive least 21 day remain investigational site transfer another institution intubate 21day study period Willing able provide write informed consent , unconscious alter sensorium , surrogate provide write informed consent approve institution Negative pregnancy test within 7 day prior randomization female childbearing potential ( Negative pregnancy test result [ urine serum ] obtain reason purpose study acceptable . ) Current diagnosis pneumonia ( Patients currently receive antibiotic treatment pneumonia patient meet study definition clinically define pneumonia time screen exclude . ) Absolute neutrophil count le 1000/mm3 Human immunodeficiency virus infection last known CD4 count le 500/mm3 Recipient organ transplantation receive immunosuppressive therapy Current hematologic malignancy Previously document cystic fibrosis Severe craniofacial trauma medical condition expect require imminent tracheostomy Patient , patient â€™ family and/or physician favor aggressive medical management presence advance directive withhold lifesustaining treatment Moribund state expect survive less 21 day due uncorrectable medical condition Participation clinical trial unlicensed drug , biologic device within 30 day prior first dose study drug Concurrent participation clinical trial unlicensed drug , biologic device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>ventilator-associated pneumonia</keyword>
	<keyword>VAP</keyword>
	<keyword>pneumonia</keyword>
	<keyword>ICU infection</keyword>
</DOC>